Literature DB >> 18544197

Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR.

H R van Doorn1, D D An, M D de Jong, N T N Lan, D V Hoa, H T Quy, N V V Chau, P M Duy, D Q Tho, N T Chinh, J J Farrar, M Caws.   

Abstract

SETTING: Pham Ngoc Thach Hospital for Tuberculosis and Lung Diseases, Ho Chi Minh City, Vietnam.
OBJECTIVE: Fluoroquinolones (FQs) are increasingly used in the treatment of tuberculosis (TB) and are the second-line drugs of choice for treatment of multidrug-resistant TB. We aimed to set up a polymerase chain reaction (PCR) based assay to detect the most common FQ-resistance-associated mutations in gyrase A (gyrA) of Mycobacterium tuberculosis.
DESIGN: A total of 42 FQ-resistant and 40 FQ-susceptible isolates were collected in 2005-2006 and sequenced in gyrA. Using sequencing results as gold standard, a real-time PCR using three locked nucleic acid probes (LNA-PCR) was designed to detect mutations at positions 90, 91 and 94 (97% of gyrA FQ-resistance-associated mutations) and evaluated.
RESULTS: Sequencing of 42 FQ-resistant isolates revealed no gyrA mutations in 10 isolates, 20 isolates had a single mutation and 12 isolates showed double peaks at resistance-associated alleles, suggesting a heterogeneous population. With LNA-PCR, all wild-type and 19/20 mutant isolates were correctly identified. Eleven of 12 heterogeneous isolates were correctly identified as resistant mutants. Overall, 71% ([19 + 11]/42) of phenotypically FQ-resistant isolates were detected. Specificity was 100% on 40 FQ-susceptible isolates.
CONCLUSION: This assay provides a simple and rapid means to reliably detect FQ-resistance-associated gyrA mutations in M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544197

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  19 in total

Review 1.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

2.  Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis.

Authors:  Wei-Lun Huang; Ting-Lin Chi; Mei-Hua Wu; Ruwen Jou
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

3.  Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis.

Authors:  Vo Sy Kiet; Nguyen Thi Ngoc Lan; Duong Duy An; Nguyen Huy Dung; Dai Viet Hoa; Nguyen van Vinh Chau; Nguyen Tran Chinh; Jeremy Farrar; Maxine Caws
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

4.  DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.

Authors:  Alix Pantel; Stéphanie Petrella; Stéphanie Matrat; Florence Brossier; Sylvaine Bastian; Delphine Reitter; Vincent Jarlier; Claudine Mayer; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

5.  Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.

Authors:  Melisa Willby; R David Sikes; Seidu Malik; Beverly Metchock; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

6.  Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.

Authors:  Alix Pantel; Stéphanie Petrella; Nicolas Veziris; Florence Brossier; Sylvaine Bastian; Vincent Jarlier; Claudine Mayer; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

7.  Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens.

Authors:  Doris Hillemann; Sabine Rüsch-Gerdes; Elvira Richter
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

8.  Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones.

Authors:  Lulette Tricia C Bravo; Marion J Tuohy; Concepcion Ang; Raul V Destura; Myrna Mendoza; Gary W Procop; Steven M Gordon; Geraldine S Hall; Nabin K Shrestha
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

9.  Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.

Authors:  Andrea Von Groll; Anandi Martin; Pontus Jureen; Sven Hoffner; Peter Vandamme; Françoise Portaels; Juan Carlos Palomino; Pedro Almeida da Silva
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

10.  Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa.

Authors:  Thomas R Ioerger; Sunwoo Koo; Eun-Gyu No; Xiaohua Chen; Michelle H Larsen; William R Jacobs; Manormoney Pillay; A Willem Sturm; James C Sacchettini
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.